Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Biotinylated Human IL-2 R alpha / CD25 Protein, His,Avitag™, premium grade, 25 µg  

Recombinant Biotinylated Human IL-2 R alpha / CD25 Protein, His,Avitag™, premium grade, 25 µg

Recombinant Biotinylated Human IL-2 R alpha / CD25 Protein, AA Glu 22 - Cys 213, expressed from human 293 cells (HEK293), His,Avitag™, premium grade

Synonym: Recombinant, human, protein, IL2RA, CD25, p55, IL2-RA, IL-2-RA

More details

ILA-H82E6-25

Availability: within 7 days

468,00 €

Background
Interleukin-2 receptor subunit alpha (IL2RA) is also known as IL-2R subunit alpha, IL-2-RA, IL2-RA, TAC antigen, p55, CD antigen CD25, is a type I transmembrane glycoprotein. IL2RA is expressed on activated T cells and regulatory T cells, and is capable of binding IL2 with low affinity by itself. However, a ligand-induced high affinity heterotrimeric receptor complex is produced when IL2RA is associated non-covelently with the IL2 receptor beta and gamma chain, and subsequently initiates the intacellular signal pathways such as MAPK or JAK/STAT. On dendritic cells (DC), CD25 has been previously regarded as an activation marker, while both murine and human DC can express CD25, they do not express the beta-chain of the IL-2 receptor, which is indispensable for the execution of IL-2 signaling.

Source
Recombinant Biotinylated Human IL-2 R alpha protein,  His,Avitag, premium grade(ILA-H82E6) is expressed from human 293 cells (HEK293). It contains AA Glu 22 - Cys 213 (Accession # P01589-1).
Predicted N-terminus: Glu 22
Biotinylated Human IL-2 R alpha, His,Avitag, premium grade (ILA-H82E6), designed for preclinical stage, has the same activity and performance with GMP Biotinylated Human IL-2 R alpha, which enables a seamless transition from preclinical development to clinical phases. Premium Grade product offer a cost efficient alternative of GMP Grade products for the early development phase when safety of raw materials is not top priority. By using Premium Grade products in early development phase, you can transition easily into clinical and commercial phase without need to revalidate the raw materials and modify manufacturing process.

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).
The protein has a calculated MW of 25.4 kDa. The protein migrates as 35-45 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Biotinylation
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

Biotin:Protein Ratio
Passed as determined by the HABA assay / binding ELISA.

Endotoxin
Less than 0.1 EU per μg by the LAL method.

Sterility
Negative

Mycoplasma
Negative.

Purity
>90% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1)  "Inflamma-miRs Profile in Myelodysplastic Syndrome Patients"
Montes, Rusanova, Cornejo et al
Int J Mol Sci (2024) 25 (12)
(2)  "Enhanced and sustained T cell activation in response to fluid shear stress"
Sarna, Desai, Kaufman et al
iScience (2024) 27 (6), 109999
(3)  "Erythrocyte Membrane Coating Alleviate Immune Response and Promoted Adipogenesis in Adipose Matrix"
Chen, Guan, Liu et al
Tissue Eng Part A (2024)
Showing 1-3 of 1715 papers.